Abstract
Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Current Enzyme Inhibition
Title: Cholinesterases and Cholinesterase Inhibitors
Volume: 4 Issue: 4
Author(s): Sarka Stepankova and Karel Komers
Affiliation:
Keywords: Alzheimer's disease, cholinesterases, cholinesterase inhibitors
Abstract: Alzheimers disease is the most common neurodegenerative disorder, clinically characterized by a noticeable cognitive decline defined by a loss of memory and learning ability, together with a reduced ability to perform basic activities of daily living, and a diverse array of neuropsychiatric symptoms such as apathy, verbal and physical agitation, irritability, depression etc. Pharmacotherapy of Alzheimers disease has progressed in the past ten years from the use of psychotropic medications for sedation to the use of rational treatments aimed at neurotransmitter replacement. Only one class of medications has been extensively evaluated in clinical trials with patients with Alzheimers disease and is approved by the US Food and Drug Administration for Alzheimers disease treatment. These medications are cholinesterase inhibitors and have a significant, although modest, effect on the cognitive status of patients with Alzheimers disease.
Export Options
About this article
Cite this article as:
Stepankova Sarka and Komers Karel, Cholinesterases and Cholinesterase Inhibitors, Current Enzyme Inhibition 2008; 4 (4) . https://dx.doi.org/10.2174/157340808786733631
DOI https://dx.doi.org/10.2174/157340808786733631 |
Print ISSN 1573-4080 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6662 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Transcriptional Dysregulation in Huntington’s Disease: The Role in Pathogenesis and Potency for Pharmacological Targeting
Current Medicinal Chemistry Anti-Amyloid Aggregating Gold Nanoparticles: Can they Really be Translated from Bench to Bedside for Alzheimer's Disease Treatment?
Current Protein & Peptide Science GABAA Receptor Specific Pyrazolopyrimidines as Potential Imaging Agents: In Vivo Characteristics of a New 18F-labelled Indiplon Derivative
Current Radiopharmaceuticals Genetics of Bladder-Exstrophy-Epispadias Complex (BEEC): Systematic Elucidation of Mendelian and Multifactorial Phenotypes
Current Genomics The Potential Role of Sirtuins Regarding the Effects of Exercise on Aging- Related Diseases
Current Aging Science Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry Multiple Defects in Energy Metabolism in Alzheimers Disease
Current Drug Targets Role of TREM2 in Alzheimer's Disease and its Consequences on β- Amyloid, Tau and Neurofibrillary Tangles
Current Alzheimer Research Relevance of Nutritional Antioxidants in Metabolic Syndrome, Ageing and Cancer: Potential for Therapeutic Targeting
Infectious Disorders - Drug Targets An Insight into Molecular Mechanisms and Novel Therapeutic Approaches in Epileptogenesis
CNS & Neurological Disorders - Drug Targets <i>In Silico</i> Identification of Irreversible Cathepsin B Inhibitors as Anti- Cancer Agents: Virtual Screening, Covalent Docking Analysis and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Potential Application of Dietary Polyphenols from Red Wine to Attaining Healthy Ageing
Current Topics in Medicinal Chemistry Linking Alzheimer’s Disease and Type 2 Diabetes Mellitus via Aberrant Insulin Signaling and Inflammation
CNS & Neurological Disorders - Drug Targets Nanomedicine against Alzheimer’s and Parkinson’s Disease
Current Pharmaceutical Design Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Heat Shock Proteins and Ion Channels. Functional Interactions and Therapeutic Consequences
Current Pharmaceutical Biotechnology The Neuroprotective Role of Vesicular Monoamine Transporter 2 in Neurodegenerative Diseases
Medicinal Chemistry Role of Neurotrophic Factors in Parkinson's Disease
Current Pharmaceutical Design Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Outcomes of Perilla Seed Oil as an Additional Neuroprotective Therapy in Patients with Mild to Moderate Dementia: A Randomized Control Trial
Current Alzheimer Research